Voxeleron — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Voxeleron is a technology and services company that leverages artificial intelligence and machine learning to analyze ophthalmic images for clinical research. Its core platform, iNebula, facilitates the management, analysis, and sharing of complex imaging datasets, aiming to accelerate ophthalmic drug development by providing standardized, device-agnostic insights. Recently acquired by Voiant, Voxeleron operates as a strategic component within a larger clinical trial imaging ecosystem, serving pharmaceutical sponsors and research organizations. The company is ISO 13485:2016 certified, indicating a quality management system for medical devices.

Ophthalmology

Technology Platform

iNebula: A cloud-based, AI-powered platform for the management, standardization, and quantitative analysis of ophthalmic imaging data (primarily OCT) for clinical trials. It is device-agnostic and provides real-time data access and insights.

Opportunities

The growing ophthalmic drug pipeline and regulatory shift towards quantitative imaging biomarkers create strong demand for specialized analysis platforms.

Integration with Voiant allows for cross-selling into a broader client base and offering a full-service imaging solution across therapeutic areas.

The trend towards decentralized and digital clinical trials further boosts the need for cloud-based, collaborative platforms like iNebula.

Risk Factors

Integration challenges following the Voiant acquisition could disrupt operations and client service.

The company faces competition from other imaging CROs and emerging AI software firms, requiring continuous innovation.

Its business is tied to the cyclicality of biopharma R&D spending and is subject to stringent data security and medical device software regulations.

Competitive Landscape

Voxeleron competes with other specialized ophthalmic imaging CROs (e.g., Heidelberg Engineering's reading center services, notional competitors), general imaging core labs that have ophthalmology divisions, and a growing number of AI-focused startups developing ophthalmic analysis software. Its acquisition by Voiant differentiates it by providing scale, a wider service portfolio, and potentially more integrated data flow across different imaging modalities beyond ophthalmology.

More companies in Digital Health & Biotech SaaS →More companies in United States →